Responding to today’s announcement by NICE that it has brought forward a reappraisal of chemotherapy drug Abraxane for patients with secondary (advanced) pancreatic cancer in England, following approval in Wales and Scotland, Alex Ford, Chief Executive of Pancreatic Cancer UK said:
“This decision is great news. There is a clear need for this treatment, which is proven to be effective, to be available to all eligible pancreatic cancer patients throughout the UK. It is currently available in Wales and Scotland but not in England or Northern Ireland.
“Treatment options available to people with pancreatic cancer are extremely limited. Survival rates have barely changed in 40 years. This appalling disease is all too often diagnosed devastatingly late and Abraxane, when used in combination with standard chemotherapy, is one of the biggest advances in twenty years. It has the potential to benefit hundreds of patients and their families meaning more precious and valuable time together.
“That is why, over the past two years, we have campaigned and worked hard with others, in public and behind the scenes, to try to ensure Abraxane is made available free on the NHS for all eligible patients in the UK.
“We hope that the move by the drug manufacturer to reduce the cost of the drug will lead to a positive outcome.”
Read more about NICE's decision here